Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Canada / NCT03362658
Active, not recruiting Observational

Novel MRI Biomarkers for Monitoring Disease Progression in ALS

NCT03362658 · tracked via the Priya Life Science Canada tracker
Sponsor
University of Alberta
Phase
Observational
Started
2016-10
Last updated
2026-05-08

Condition(s) studied

Amyotrophic Lateral SclerosisMotor Neuron Disease

Study summary

Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a "biomarker") by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our understanding of ALS and provide a means to diagnose it sooner and monitor its progression. Importantly, we expect these techniques to improve how new drugs are tested, which may lead to the more rapid discovery of a treatment for ALS.

Each participant will have 3 MRI scans over a period of 8 months, along with neurological and cognitive evaluations. Study visits will take 2 - 3 hours. MRI is a safe technique that does not involve radiation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with a suspected or confirmed diagnosis as described in Study Populations * For those with a diagnosis of ALS, patients will be considered with an El Escorial classification of suspected, possible, probable, probable lab-supported, and definite ALS. * Patients 18 years of age or older * Healthy controls over the age of 40. * Be able to lie in an MRI machine for approximately 60 minutes Exclusion Criteria: * Subjects with psychiatric/CNS illnesses such as Major Depressive Disorder, Schizophrenia, and Bipolar disorder. * Subjects with significant head injury or other neurological disease (stroke, brain tumour). * Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign body.

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
University of Miami Miami Florida
University of Utah Salt Lake City Utah
University of Calgary / Heritage Medical Research Clinic Calgary Alberta
University of Alberta Edmonton Alberta
University of Toronto / Sunnybrook Health Sciences Centre Toronto Ontario
McGill University / Montreal Neurological Institute and Hospital Montreal Quebec
Laval University Québec Quebec

More University of Alberta trials in Canada

30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants Recruiting
Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study Recruiting
Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD Active, not recruiting
Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy Recruiting
Multidisciplinary Support To Access Living Donor Kidney Transplant-Pilot Active, not recruiting

Other trials for the same condition

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS Recruiting
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis Recruiting
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS Active, not recruiting
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS Active, not recruiting
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03362658 on ClinicalTrials.gov ↗ ← All trials in Canada